| ●Editorial | Saruta T，Fukushima M | 5-6 |
| ●Public Debriefing Session 2011 Life science innovation：The growing role of academia in Japan Organized by：Foundation for Biomedical Research and Innovation | 7-216 | |
| Annual Reports of Translational Research 2011 | Saruta T | 13 |
| Importance of investigator-initiated clinical trial and translational research for promotion of new drug development in Japan introduced by amendment of the Pharmaceutical Affairs Law in 2002 | Doi O | 17-9 |
| Mission and achievement of MEXT national translational research promotion program | Fukushima M | 20-5 |
| Overview from the Supporting Organization | Nagai Y | 29-33 |
| All Hokkaido Translational Research Project for Advanced Medicine, success obtained from the five years and future task | Shimamoto K | 34-8 |
| The formation of the Translational Research based on the co-development with Biomedical Engineering－ Innovation of New Biomedical Engineering Center “Tohoku University：Achievements and Assignments” | Satomi S | 39-43 |
| Center for development of advanced medical technology | Nagai R | 44-8 |
| Five-year outcome from Kyoto University －Academic base for development of new drug and advanced medical treatment－ | Shimizu A | 49-52 |
| Establishment of strategic and functional institute for translational research | Sawa Y | 53-7 |
| Translational research center for regenerative medicine and cell therapy | Kawamata S，Nabeshima Y | 58-61 |
| Base for the development of innovative bio-medicine and bio-medical devices “Achievement and task of Kyushu University” | Nakanishi Y | 62-6 |
| Plenary discussion | 67-8 | |
| Review and vision for the future | Koga T | 69-72 |
| Introduction | 75-6 | |
| Strengthening the capability of science & technology driven innovation ～Establishment of an engine for the integrated promotion of education, science & technology and innovation～ | Tsuge A | 77-83 |
| Cancer therapy by humanized anti-PD-1 antibody | Honjo T | 84-7 |
| Discussion | 88-9 | |
| Thought on the medical science and research：circulation of medical knowledge | Nagai R | 90-5 |
| The way of industry-academia-government collaboration | Nogimori M | 96-100 |
| Discussion | 101 | |
| Panel discussion | 102-5 | |
| Introduction | 109 | |
| A novel type of intrinsic pluripotent stem cells, Muse cells, and their potential for regenerative medicine | Dezawa M | 110-20 |
| Current status of regenerative medicine clinical trials and potentials of Japanese academia | Nagai Y | 121-5 |
| Current status of the important patents | Yamanaka A | 126-30 |
| How to deal with patent infringement | Matsutoya Y | 131-6 |
| Intellectual property management and strategic intellectual property rights acquisition | Takeda H | 137-9 |
| Clinical study of cardiac regenerative therapy using myoblast sheets for severe heart failure | Sawa Y | 140-2 |
| Cardiac Regeneration therapy using Autologous human Cardiac stem cell：The ALCADIA Trial | Takehara N | 143-8 |
| Plenary discussion | 149 | |
| PMDA’s efforts to develop seeds of Japanese origin for innovative drugs and devices | Kondo T | 153-7 |
| Achievement of clinical trials proposed by the initiative of medical doctors and application for approval of medical devices by collaborations among All Hokkaido 3 medical universities | Shirato H | 158-61 |
| Investigator-conducted clinical trial of the HB-EGF inhibitor BK-UM | Mekada E | 162-6 |
| Overview of SENSHIN IRYOU SEIDO | Sakoi M | 167-72 |
| Islet Transplantation using potent induction immunotherapy | Gotoh M | 173-7 |
| Regenerative medicine by sustained release of bFGF using gelatin hydrogel in Cardiovascular Field | Sakata R | 178-81 |
| Clinical trial designs for early drug development：Implications for design with targeted agents | Crowley J | 185-90 |
| Statistical evaluation of surrogate endpoints | Teramukai S | 191-5 |
| Discussion | 196-7 | |
| Current status and future scope of CDISC standards | Kush RD | 198-204 |
| CDISC activities in TRI | Jyono T | 205-9 |
| Discussion | 210-1 | |
| Closing remarks | Fukushima M | 215-6 |
| ●CDISC as the global standards | ||
| CDISC standards and innovations | Vadakin A，Kush RD | 217-28 |
| ・Full text version in English is here ! | ||
| ●Instructions for authors [Japanese] & [English] | 229-30 |